STOCKHOLM, April 8, 2024 /PRNewswire/ — Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (“Calliditas”), today announced upcoming data presentations,…
Browsing: Calliditas Therapeutics
STOCKHOLM, Jan. 7, 2024 /PRNewswire/ — Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (“Calliditas”), a commercial biopharma company focused…
STOCKHOLM, Dec. 20, 2023 /PRNewswire/ — Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (“Calliditas”), today announced that the U.S. Food…
STOCKHOLM, Nov. 7, 2023 /PRNewswire/ — The Lancet publication of full Phase 3 data set In August we were excited…
STOCKHOLM, Oct. 23, 2023 /PRNewswire/ — It is hereby announced that Calliditas Therapeutics’s major owners have appointed a nomination committee for…
STOCKHOLM, Oct. 5, 2023 /PRNewswire/ — Calliditas Therapeutics AB (Nasdaq: CALT) (Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that the European…
STOCKHOLM, Sept. 29, 2023 /PRNewswire/ — Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) (“Calliditas”), today announced the presentations of…
Filing for full approval of TARPEYO STOCKHOLM, Aug. 17, 2023 /PRNewswire/ — FINANCIAL SUMMARY FOR THE GROUP Key Figures April…
STOCKHOLM, July 13, 2023 /PRNewswire/ — Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) (“Calliditas”) today announced interim data from…